In his weekly clinical update Dr. Griffin discusses China reporting almost 60,000 Covid-related deaths after abrupt shift in policy, detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination, effect of Fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19, hyperimmune globulin for severely immunocompromised patients hospitalized with COVID-19, long COVID outcomes at one year after mild SARS-CoV-2 infection, long COVID: major findings, mechanisms and recommendations, a systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on World Health Organization international clinical trials platform, and the effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome.

In his weekly clinical update Dr. Griffin discusses poliovirus returns to New York wastewater, COVID-19 is more widespread in animals than we thought, increasing ventilation reduces SARS-CoV-2 airborne transmission in schools, the use of carbon dioxide monitoring to assess ventilation at a national infectious diseases conference, effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes, 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection, and long COVID outcomes at one year after mild SARS-CoV-2 infection.

In his weekly clinical update Dr. Griffin discusses the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans, time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir, COVID drug Paxlovid was hailed as a game-changer, what happened?, the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID — even with a mild case.

In his weekly clinical update Dr. Griffin discusses modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China, canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event, two masks can be worse than one: N95 respirator failure caused by an overlying face mask, airflow patterns in double-occupancy patient rooms may contribute to roommate-to-roommate transmission of severe SARS-CoV-2, clinical validation of a novel T-Cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection, antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant, VV116 versus Nirmatrelvir–Ritonavir for oral treatment of Covid-19, Nirmatrelvir plus Ritonavir for early COVID-19 in a U.S. health system, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, higher dose corticosteroids in hospitalized COVID-19 patients with hypoxia but not requiring ventilatory support, FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults, structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction, persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium, epidemiology of long COVID in US adults, persistent symptoms and sequelae after SARS-CoV-2 infection not requiring hospitalization, and outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.

In his weekly clinical update Dr. Griffin discusses how immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged <18 years who were hospitalized or died with Influenza, WHO estimates of excess mortality associated with the COVID-19 pandemic, reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection post-vaccination for mild COVID-19 patients, impact of SARS-CoV-2 variants on inpatient clinical outcome, clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents, similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples from symptomatic children during Delta and Omicron surges, early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19, effect of Nirmatrelvir/Ritonavir vs Placebo on COVID-19─related hospitalizations and other medical visits, COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization, bacterial co-infection and empirical antibiotic therapy in patients with COVID-19, association of time to surgery after COVID-19 infection with risk of postoperative cardiovascular morbidity, demonstration of stable clusters of symptoms in long COVID, and how longitudinal analysis of t cells in COVID-19 survivors with post-acute sequelae of COVID-19 reveals associations between individual symptoms and inflammatory indexes.

In his weekly clinical update Dr. Griffin discusses Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022, triage of patients with Ebola virus disease, SARS-CoV-2 serology and self-reported infection among adults, serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals, sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants, effect of wearing glasses on risk of infection with SARS-CoV-2 in the community, and data-driven identification of post-acute SARS-CoV-2 infection subphenotypes.

In his weekly clinical update Dr. Griffin discusses effectiveness of influenza vaccination of pregnant women for prevention of maternal and early infant Influenza-associated hospitalizations in South Africa, a multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes, single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic induce durable B cell memory responses comparable to replicating smallpox vaccines, whether the risk of still and preterm birth is affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy, medical masks versus N95 respirators for preventing COVID-19 among health care workers, alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, real-world evidence of novel treatments for COVID-19 on mortality: a nationwide comparative cohort study of hospitalized patients in the 1st, 2nd, 3rdand 4th wave in the Netherlands, and effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19.

In his weekly clinical update Dr. Griffin discusses human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks, changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, updates on COVID-19–related mortality, impact of community masking on COVID-19, effectiveness of the COVID-19 vaccines against hospitalization with Omicron sub-lineages BA.4 and BA.5 in England, cardiovascular outcomes after Tixagevimab and Cilgavimab use for pre-exposure prophylaxis against COVID-19, how Paxlovid is associated with decreased hospitalization rate among adults with COVID-19, inside the mind of an anti-paxxer, and angiotensin receptor blockers for the treatment of COVID-19.